Jazz Pharmaceuticals PLC (JAZZ) Position Boosted by Andra AP fonden

Andra AP fonden increased its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 60.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,200 shares of the specialty pharmaceutical company’s stock after buying an additional 3,100 shares during the period. Andra AP fonden’s holdings in Jazz Pharmaceuticals PLC were worth $1,199,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Emerald Advisers Inc. PA increased its holdings in Jazz Pharmaceuticals PLC by 17.5% during the third quarter. Emerald Advisers Inc. PA now owns 9,680 shares of the specialty pharmaceutical company’s stock worth $1,416,000 after buying an additional 1,442 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in Jazz Pharmaceuticals PLC by 23.9% during the third quarter. Rice Hall James & Associates LLC now owns 18,459 shares of the specialty pharmaceutical company’s stock worth $2,700,000 after buying an additional 3,563 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Jazz Pharmaceuticals PLC by 177.7% during the third quarter. Victory Capital Management Inc. now owns 9,468 shares of the specialty pharmaceutical company’s stock worth $1,385,000 after buying an additional 6,058 shares during the last quarter. First Manhattan Co. increased its holdings in Jazz Pharmaceuticals PLC by 36.8% during the third quarter. First Manhattan Co. now owns 2,600 shares of the specialty pharmaceutical company’s stock worth $380,000 after buying an additional 700 shares during the last quarter. Finally, Highstreet Asset Management Inc. acquired a new position in Jazz Pharmaceuticals PLC during the third quarter worth $425,000. Institutional investors and hedge funds own 88.91% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Position Boosted by Andra AP fonden” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/14/jazz-pharmaceuticals-plc-jazz-position-boosted-by-andra-ap-fonden.html.

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total transaction of $153,520.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick G. Enright sold 351 shares of the company’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $148.40, for a total transaction of $52,088.40. Following the sale, the director now directly owns 1,717 shares of the company’s stock, valued at approximately $254,802.80. The disclosure for this sale can be found here. Insiders have sold 2,351 shares of company stock valued at $355,608 in the last ninety days. 4.30% of the stock is currently owned by company insiders.

JAZZ has been the topic of a number of recent analyst reports. FBR & Co started coverage on shares of Jazz Pharmaceuticals PLC in a report on Thursday, October 19th. They set a “buy” rating and a $206.00 target price on the stock. Wells Fargo & Company reiterated an “outperform” rating and issued a $177.00 price objective (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. BidaskClub downgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Royal Bank Of Canada decreased their price objective on shares of Jazz Pharmaceuticals PLC from $210.00 to $195.00 and set an “outperform” rating on the stock in a report on Wednesday, November 8th. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, August 29th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and eighteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $180.13.

Shares of Jazz Pharmaceuticals PLC (JAZZ) opened at $136.47 on Tuesday. Jazz Pharmaceuticals PLC has a 52-week low of $99.28 and a 52-week high of $163.75. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10. The firm has a market cap of $8,315.13, a PE ratio of 17.40, a P/E/G ratio of 0.82 and a beta of 1.00.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply